- Home
- KLG vs TVTX Comparison
KLG vs TVTX Comparison
Compare KLG & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLG
- TVTX
- Stock Information
- Founded
- KLG 2022
- TVTX 2008
- Country
- KLG United States
- TVTX United States
- Employees
- KLG N/A
- TVTX N/A
- Industry
- KLG Packaged Foods
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- KLG Consumer Staples
- TVTX Health Care
- Exchange
- KLG Nasdaq
- TVTX Nasdaq
- Market Cap
- KLG 1.4B
- TVTX 1.5B
- IPO Year
- KLG N/A
- TVTX N/A
- Fundamental
- Price
- KLG $23.03
- TVTX $18.82
- Analyst Decision
- KLG Hold
- TVTX Strong Buy
- Analyst Count
- KLG 6
- TVTX 16
- Target Price
- KLG $20.17
- TVTX $33.40
- AVG Volume (30 Days)
- KLG 918.4K
- TVTX 1.5M
- Earning Date
- KLG 08-07-2025
- TVTX 08-06-2025
- Dividend Yield
- KLG 2.87%
- TVTX N/A
- EPS Growth
- KLG N/A
- TVTX N/A
- EPS
- KLG 0.35
- TVTX N/A
- Revenue
- KLG $2,605,000,000.00
- TVTX $333,865,000.00
- Revenue This Year
- KLG N/A
- TVTX $71.61
- Revenue Next Year
- KLG N/A
- TVTX $43.45
- P/E Ratio
- KLG $66.59
- TVTX N/A
- Revenue Growth
- KLG N/A
- TVTX 87.94
- 52 Week Low
- KLG $14.80
- TVTX $8.46
- 52 Week High
- KLG $23.56
- TVTX $25.29
- Technical
- Relative Strength Index (RSI)
- KLG 69.24
- TVTX 74.85
- Support Level
- KLG $23.00
- TVTX $15.60
- Resistance Level
- KLG $23.12
- TVTX $17.46
- Average True Range (ATR)
- KLG 0.17
- TVTX 0.83
- MACD
- KLG -0.24
- TVTX 0.26
- Stochastic Oscillator
- KLG 39.62
- TVTX 98.44
About KLG WK Kellogg Co
WK Kellogg is the second-largest cereal manufacturer in North America. Its cereal brands include Special K, Frosted Flakes, Raisin Bran, Froot Loops, Frosted Mini-Wheats, Kashi, Corn Flakes, Rice Krispies, Apple Jacks, and Bear Naked. The company was spun off from the former Kellogg business, now known as Kellanova, where the former firm's global snacks portfolio and international cereal brands are now housed. WK Kellogg, which began trading independently in October 2023, generates the bulk of its sales (about 88% of its fiscal 2024 base) in the US.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.